Table 4.

Incidence and categories of hyperglycemia in accordance to scheme of GC therapy

Variable	CGC n = 12	CyGC n = 20	P*
PAD (mg/patient)
8 weeks	4200	1500	-
12 weeks	-	2500	-
Fasting hyperglycemia (≥5.60 mmol/L)
Incidence, n (%)	12 (100)	10 (50)	0.003*
Plasma glucose (mmol/L)	8.22 ± 3.79	6.50 ± 0.64	0.16
Prediabetes (≥5.60- < 7.00 mmol/L)
Incidence, n (%)	5 (41.6)	6 (30)	0.51
DM (fasting glycemia ≥7.00 mmol/L)
Incidence, n (%)	7 (58.3)	4 (20)	0.22
Plasma glucose (mmol/L)	9.83 ± 4.39	7.11 ± 0.15	0.26
DM occurrence - week, n (%)
First	0 (0)	0 (0)	-
Second to fourth	5 (71.4)	0 (0)	-
Fifth to eighth	2 (28.5)	4 (100)	-
Postprandial hyperglycemia
Incidence, n (%)	1 (8.3)	4 (20)	0.62

All data are reported in total number of subjects and (%) or mean ± SD.

CGC, continuous glucocorticoid regimen; CyGC, cyclic glucocorticoid regimen; PAD, prednisone accumulative dose; DM, diabetes mellitus.

*Significant P value ≤0.05.